Concerning the identification of biomarkers predicting therapeutic responses to AZA in MDS, an earlier study reported that mutations in the Ten-Eleven Translocation 2 (TET2) gene impacted the outcome of AZA treatment; the response rate for AZA treatment was higher in patients with mutant TET2 than wild-type TET2 [9]. This evidence concerns the gene TET2 and myelodysplastic syndrome.